AURA earnings analysis
What we found in AURA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The provided 10-Q text does not include quarterly income statement, balance sheet or cash flow results, so revenue, margins, EPS, free cash flow and segment trends cannot be assessed. The filing reiterates an expected cash runway into the first half of 2029 and confirms completion of Phase 3 enrollment, but topline data are not expected until the second half of 2027. Financial pressure remains significant, with six-month net loss rising to $79.3 million from $54.5 million year over year and accumulated deficit reaching $559.7 million.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Cash runway into 1H 2029
- Management states that existing cash, cash equivalents and marketable securities are sufficient to fund operations into the first half of 2029.
- Phase 3 enrollment completed
- The company completed enrollment in its global Phase 3 trial of bel-sar and expects topline data in the second half of 2027.
- Disclosure controls deemed effective
- As of June 30, 2026, management concluded that disclosure controls and procedures were effective, and reported no material changes in internal control over financial reporting during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Losses continue to expand
- Net loss increased to $79.3 million for the six months ended June 30, 2026, from $54.5 million in the comparable 2025 period, an increase of $24.8 million or approximately 45.5%. Accumulated deficit reached $559.7 million as of June 30, 2026.
- Long wait for pivotal data
- Although enrollment is complete, management does not expect topline Phase 3 data until the second half of 2027; final results could be negative, inconclusive or insufficient to support approval.
- 20% workforce reduction
- The company approved an organizational streamlining plan in August 2026 focused on ocular oncology, including an approximately 20% workforce reduction. Management warns that the reductions could result in loss of institutional knowledge and reallocation of responsibilities.
What they said about what is next.
The provided filing text does not include quantitative revenue or EPS guidance. Management states that existing cash, cash equivalents and marketable securities are expected to fund operations into the first half of 2029; formal outlook was not provided.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 11, 2026
- Aura Biosciences, Inc. reported its Q4 2026 results, marking continued financial strain with a net loss of $33.7 million, reflecting an increase from $27.5 million a year prior. Despite these losses, the company has…
- 10-K · March 30, 2026
- Aura Biosciences is a clinical‑stage biotech focused on belzupacap sarotalocan (bel‑sar), a virus‑like drug conjugate (VDC) being advanced as a vision‑sparing therapy in ocular oncology and in bladder cancer (NMIBC).…
- 10-Q · November 13, 2025
- Aura reported Q3 2025 net loss of $26,130,000 (diluted EPS $(0.40)), versus $21,042,000 (EPS $(0.42)) in Q3 2024; operating expenses rose to $27,906,000 from $23,232,000. The company strengthened its liquidity via a…
- 10-Q · August 13, 2025
- Aura Biosciences reported a net loss of $27.019 million in Q2 2025, resulting in an EPS of -$0.47, slightly improving from -$0.41 in Q2 2024. Key highlights include a strong increase in cash and equivalents to $107.367…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing AURA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever